Newsletter Subject

Huge Study Throws Cold Water on Antimalarials for COVID-19

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Sat, May 23, 2020 10:09 AM

Email Preheader Text

Daily Headlines Saturday, May 23, 2020 CME SPOTLIGHT ADVERTISEMENT CME SPOTLIGHT CME SPOTLIGHT CME S

[MEDPAGE TODAY]( Daily Headlines Saturday, May 23, 2020 [INFECTIOUS DISEASE]( [Huge Study Throws Cold Water on Antimalarials for COVID-19]( [PUBLIC HEALTH & POLICY]( [Claims Data Could Economize Trials' Endpoint Adjudication]( [ENDOCRINOLOGY]( [Subacute Thyroiditis Tied to COVID-19; Dairy and MetSyn Risk]( CME SPOTLIGHT [Improving Patient Outcomes in Follicular Lymphoma Through Quality Care Initiatives]( [MEETING COVERAGE]( [Positive Data for Novel Oral Migraine Treatment]( [PSYCHIATRY]( ['A Lot of Bouncing Around': What We Heard This Week]( ADVERTISEMENT [INFECTIOUS DISEASE]( [Autopsies Turn Up Strange Feature of COVID-19 Lungs]( CME SPOTLIGHT [New and Emerging Treatment Options for Refractory HER2+ Metastatic Breast Cancer]( [INFECTIOUS DISEASE]( [House Members Concerned About PPE Supplies, China's Role in COVID-19]( [MEETING COVERAGE]( [Leukemia Drug for Parkinson's: A Second Look]( [ONCOLOGY/HEMATOLOGY]( [RT Plus ADT Tops Brachytherapy Boost for Prostate Cancer]( CME SPOTLIGHT [Real-World Strategies to Support Oncology Teams Who Care for Women with Recurrent Ovarian Cancer]( [ACR READING ROOM]( [Study Reshapes Framework for Treat to Target in Psoriatic Arthritis]( [AMERICAN COLLEGE OF RHEUMATOLOGY]( [Philip Mease, MD, on Which Patients With Psoriatic Arthritis Are Most Likely to Achieve Optimal Outcomes With Apremilast]( [INFECTIOUS DISEASE]( [COVID-19 Vax Safe, Produced Responses in Healthy Chinese Adults]( CME SPOTLIGHT [Navigating the Rapidly Evolving Treatment Landscape for HER2+ Metastatic Breast Cancer]( [ASCO READING ROOM]( [Melanoma: Mature Data Show Both High-Dose IF and High-Dose Ipi Are Non-Optimal as Adjuvant Tx]( [ASCO]( [Ahmad Tarhini, MD, PhD, on Ipilimumab and High-Dose IF in High-Risk Melanoma]( [INFECTIOUS DISEASE]( [Seniors' Safety During Pandemic Gets Senate Hearing]( CME SPOTLIGHT [Improving Patient-Centered Care in Relapsed/Refractory DLBCL]( CME/CE [Risks Not Often Mentioned on Websites for Lung Cancer Screening]( CME/CE [Will a Blood Test Revolutionize Alzheimer's Diagnosis?]( [ASCO READING ROOM]( [BEACON CRC Results Support New Standard of Care in Metastatic Colorectal Cancer With BRAF Mutations]( CME SPOTLIGHT [Approaches for Early Diagnosis, Risk Stratification, and Multidisciplinary Management of Stage I/II Melanoma]( [ASCO]( [Scott Kopetz, MD, PhD, on Quality-of-Life Data From the Colorectal Cancer BEACON Study]( CME SPOTLIGHT [Advancing Myelofibrosis Care: Expert Answers to Real-World Questions]( CME SPOTLIGHT [Teaming Up to Improve Hemophilia Control: Learning Sessions for Patients, Caregivers, and Health Care Providers]( Career Center [Oncologist]([APPLY >]( Modesto, CA | Sutter Gould Medical Foundation Northern California Hematology/Oncology Opportunity... # Weekly Survey [Should Hospitals Reopen to Visitors?]( Coronavirus cases have decreased or stabilized [in many states](, and access to PPE has improved[VOTE >]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? Medpage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2020 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Daily_DHE?xid=nl_mpt_DHE_2020-05-23&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 345 Hudson Street 16th Floor New York, NY 10014

Marketing emails from medpagetoday.com

View More
Sent On

08/12/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

07/11/2024

Sent On

06/11/2024

Sent On

04/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.